Project Grant R01HL179065
Award Date
6/1/25
Completion Date
3/31/30
Dollars Obligated
$798K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Nashville, TN 37203, USA
Similar Awards
This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $5,715,866 to develop novel, transformative therapies that reduce the burden of morbidity and mortality from progressive pulmonary fibrosis (PF). The 5-year project, awarded on September 17, 2024, aims to re-shape understanding of the natural history of PF by investigating transcriptomic, genetic, epigenetic, metabolic, and environmental factors that contribute to...
This $774,585 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837) supports research to investigate the role of inflammatory fibroblasts in pulmonary fibrosis. The key objectives are to: Determine the mechanisms driving the emergence of inflammatory fibroblasts from normal alveolar fibroblasts and how these cells modulate inflammatory responses and fibrosis in different lung injury models....
This $940,320 Cooperative Agreement award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will support a multi-year research project led by Vanderbilt University Medical Center (VUMC) to investigate the molecular mechanisms underlying chronic lung diseases, including pulmonary fibrosis and bronchopulmonary dysplasia. The key objectives are to: 1) develop a detailed spatial molecular atlas of chronic lung diseases, 2)...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), provides $277,610 to Duke University to support research on the role of TP53 regulation in alveolar epithelial transitional cell state and its contribution to pulmonary fibrosis. The research aims to uncover the molecular mechanisms that drive alveolar epithelial cell transitions and their potential impact on the pathogenesis of...
This federal Project Grant award, in the amount of $1,546,880, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The grant supports research to investigate the regulation of the myofibroblast program in idiopathic pulmonary fibrosis. The research aims to determine the "regulatory architecture" of open chromatin in myofibroblasts, explore how expression levels of E-box transcription factors regulate...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $604,115 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to conduct a longitudinal observational study. The study aims to determine if advanced PET and MRI imaging techniques can predict the development of progressive pulmonary fibrosis in individuals with non-idiopathic pulmonary fibrosis...
This federal Project Grant award of $542,402 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to identify small molecule compounds that can reverse profibrotic gene signatures in idiopathic pulmonary fibrosis (IPF). The research team from the collaborative partnership of Henry Ford Health and Michigan State University Health Sciences will pursue a three-part approach: 1) in silico discovery of drug...
This $193,378 federal Project Grant award, funded by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research led by Dr. Christina Eckhardt at Columbia University to develop an exosomic signature to identify and predict rapidly progressive idiopathic pulmonary fibrosis (IPF). The research aims to leverage plasma extracellular vesicle-derived microRNAs as novel biomarkers to improve early detection and...
This $651,019 federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to elucidate the mediators and pathways that contribute to dysfunctional epithelial repair in pulmonary fibrosis. The grant, awarded to the Regents of the University of Michigan, aims to: 1) identify factors driving dysfunctional epithelial states in persistent lung fibrosis, 2) determine the impact of...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $170,543 to Virginia Commonwealth University (VCU) for a 2-year period from September 1, 2024 to August 31, 2026. The funding supports research to characterize the mechanism by which the mechanoreceptor PIEZO2 drives metabolic adaptations in response to increased lung matrix stiffness, and how these metabolic changes contribute to...